Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8233 ARTÍCULOS , VIENDO DEL 31 AL 45

The role of microglia glucose metabolism reprogramming in Alzheimer's disease treatment

Cao Q, Shen M, Liu Y, Li C, Liu L, Zhou J, Yue R, Niu D, Ren Y, Pan L, Yao J, Zhang G.

J Alzheimers Dis. 2026 Oct;113(4):1499-1517. doi: 10.1177/13872877261478594. Epub 2026 Aug 21.

Lithium: the protective cation singled out by Alzheimer's disease

Kim SH, Lee SK.

BMB Rep. 2026 Oct;59(10):456-465. doi: 10.5483/BMBRep.2026-0134.

Curcumin nanoformulations for modulating neuroinflammation and oxidative stress in Alzheimer's disease: blood-brain barrier transport, formulation strategies and therapeutic applications

Begum MY, Rajkumar M, Govindaraj P, Prathap N, Sudha PN, Al Hamod M, Alotaibi H, Uvarajan D.

Inflammopharmacology. 2026 Oct;34(10):6519-6548. doi: 10.1007/s10787-026-02381-5. Epub 2026 Sep 2.

The lithium-magnesium-zinc axis under stress: regulation of N-glycosylation-linked proteostasis and Alzheimer's disease

Schloss JV, Nguyen T.

Inflammopharmacology. 2026 Oct;34(10):6795-6802. doi: 10.1007/s10787-026-02383-3. Epub 2026 Sep 2.

Acitretin shows promising potential in Alzheimer's disease: retinoid-driven modulation of amyloid processing, neuroinflammation, and translational prospects

Sharma V, Vashisht K, Choudhary G, Choudhay V, Bhatia V, Ashawat MS, Baldi A, Kushawaha SK.

Inflammopharmacology. 2026 Oct;34(10):6549-6560. doi: 10.1007/s10787-026-02392-2. Epub 2026 Sep 2.

Targeting cytokine-driven neuroinflammation in Alzheimer's disease: mechanistic insights and pharmacological strategies

Wasim R.

Inflammopharmacology. 2026 Oct;34(10):6487-6517. doi: 10.1007/s10787-026-02342-y. Epub 2026 Sep 4.

Investigating oral blarcamesine for treatment of early Alzheimer's disease

Chandrasekaran A, Paget-Blanc A, Decourt B, Sabbagh MN.

Expert Opin Pharmacother. 2026 Oct;27(14):1581-1589. doi: 10.1080/14656566.2026.2732056. Epub 2026 Sep 20.

Recent advances of GPR40 agonists as potential anti-Alzheimer's agents

da Silva JMA, Kümmerle AE, Rodrigues DA, Bolognesi ML, Milelli A, Lima LM, de Sena Murteira Pinheiro P.

Future Med Chem. 2026 Oct;18(20):2953-2968. doi: 10.1080/17568919.2026.2732260. Epub 2026 Oct 6.

Dementia with Lewy bodies and amyloid pathology: Eligible for anti-amyloid treatment or not?

Exalto LG, van Alphen JL, Barkhof F, Teunissen C, Vijverberg EGB, Aarsland D, Lemstra AW.

Alzheimers Dement. 2026 Oct;22(10):e71907. doi: 10.1002/alz.71907.

Targeting tau acetylation in Alzheimer's disease: Molecular mechanisms, pathological consequences, and therapeutic opportunities of dietary phytochemicals

Basavaraju KC, Priyadarshini P.

Biochem Biophys Res Commun. 2026 Nov 12;839:154717. doi: 10.1016/j.bbrc.2026.154717. Epub 2026 Oct 10.

Preclinical and first-in-human evaluation of VG-3927/SAR448851, an oral small-molecule TREM2 agonist for Alzheimer's disease

Dejanovic B, Figley MD, Weisman E, Kiragasi B, Gergits FW, Larson K, Renoux A, Rajagovindan R, Pandya B, Houze J, Huang L, Gaudreault F, O'Mara R, Clarkson JH, Turnbull MT, Meier A, Colonna M, Stromme J, Gray D, Thackaberry EA, Kaufmann P, Mirescu C.

Sci Transl Med. 2026 Oct 14;18(871):eaec5740. doi: 10.1126/scitranslmed.aec5740. Epub 2026 Oct 14.

Amyloid-β Immunotherapy in Alzheimer's Disease: Challenges and Opportunities

Nakashima S, Sato K, Niimi Y, Iwatsubo T.

Annu Rev Pathol. 2026 Oct 16. doi: 10.1146/annurev-pathmechdis-032025-030232. Online ahead of print.

Ethical challenges in the clinical translation of anti-amyloid monoclonal antibodies for Alzheimer's disease: a scoping review

Wicker A, Courtright-Lim A, Tilburt J.

Front Psychiatry. 2026 Oct 5;17:1953954. doi: 10.3389/fpsyt.2026.1953954. eCollection 2026.

Cannabidiol in Alzheimer's disease: evidence-weighted molecular mechanisms and translational challenges

Sura S, Jagadeesan S, Masrudin SS, Moklas MAM, Nor NHM.

Mol Biol Rep. 2026 Oct 23;53(1):1792. doi: 10.1007/s11033-026-13034-9.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias